At a Baird investor event, Alcon CEO David Endicott framed the next 24–36 months as “dynamic” but messy: seven launches in flight, five acquisitions in ~18 months, and a full-fleet refresh anchored by the new Unity platform. The company intends to replace its ~30,000 installed cataract/refractive systems at ~3,000 units per year over time; early rollout is retina-first and deliberate, with ~1,000 consoles already qualified or under contract in the first 90–120 days. Units are down year over year, but mix/ASPs and higher consumable attach on Unity should support margins as the refresh scales.

Market backdrop remains steady: global cataract procedures have grown ~4% for a decade (U.S. ~3% with normal volatility). Implantables have near-term competitive noise; Alcon expects them to track the market rather than drive growth until next-gen Vivity and a new monofocal arrive. Vision Care is positioned for mid-single-digit growth as flexible manufacturing (P1, P7, DT1) lets Alcon swing across modalities; P7 is pulling share from the two-week segment. In Ocular Health, Tryptyr (dry eye) should build over ~18 months as reimbursement layers in; traditional Medicare timing implies the big step-up in 2027.

On M&A, the STAAR deal thesis is distribution and G&A synergies on a rebased revenue starting point after elevated China inventory. Tariffs (~$100m in 2H) are a headwind, but pricing, supplier actions, and footprint moves aim to soften the blow. CFO Tim Stonesifer still sees ~150 bps of “natural” operating leverage this year on 4–5% revenue growth, and margin expansion again next year—partly tempered by tariffs (~50 bps) and the Aurion investment.

Conclusion

Net-net, the update by CEO Endicott supports our thesis of a multi-year recovery story. Earnings power should trend up via: (1) Unity mix/consumables lift and equipment ASPs; (2) steady mid-single-digit Vision Care; (3) operating leverage that management pegs at ~150 bps again next year, partially offset by tariffs and Aurion. Near-term drags—U.S. implantable competition, tariff costs, and a gradual Tryptyr ramp—limit upside surprise in 2025 but the setup improves into 2026 as Unity penetration broadens and STAAR synergies show, with a further step-up in 2027 when traditional Medicare coverage for Tryptyr lands. Alcon was our stock of the month in August 2025 and we see good recovery potential here.